[The antiviral action of recombinant forms of the human T-lymphocyte CD4 receptor].
A recombinant protein containing the first 179 N-terminus amino acids of human T-lymphocyte CD4-receptor was synthesized in E. coli cells. This recombinant protein was shown to interact with OKT4A and Leu3a monoclonal antibodies competing with HIV gp120 glycoprotein for binding with the native CD4 receptor. Experiments in vitro in human T-lymphocyte cultures showed that the recombinant CD4-protein in concentrations of 1 to 10 micrograms/ml inhibited the virus-induced syncytium formation, HIV replication in cell culture, synthesis of HIV reverse transcriptase and other virus-specific proteins, that is, behaved as a HIV inhibitor.
Zverev
V V
VV
Maliushova
V V
VV
Sidorov
A V
AV
Pugach
A V
AV
Shukhmina
N R
NR
Pille
E R
ER
Mel'nikova
N L
NL
Andzhaparidze
O G
OG
D000911:Antibodies, Monoclonal / Q000187:drug effects / Q000378:metabolism; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D015704:CD4 Antigens / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D015726:Giant Cells / Q000187:drug effects; D015699:HIV Envelope Protein gp120 / Q000187:drug effects / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D011485:Protein Binding / Q000187:drug effects; D012194:RNA-Directed DNA Polymerase / Q000187:drug effects; D011994:Recombinant Proteins / Q000138:chemical synthesis / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D014776:Virus Cultivation
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D011994:Recombinant Proteins; D012194:RNA-Directed DNA Polymerase